Abeona Therapeutics Inc (NASDAQ:ABEO) Holdings Lowered by Ikarian Capital LLC

Ikarian Capital LLC cut its holdings in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 24.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 583,593 shares of the biopharmaceutical company's stock after selling 185,171 shares during the quarter. Ikarian Capital LLC owned approximately 1.35% of Abeona Therapeutics worth $3,688,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ABEO. Bank of New York Mellon Corp increased its holdings in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after buying an additional 2,434 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $151,000. GSA Capital Partners LLP increased its holdings in shares of Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company's stock valued at $607,000 after acquiring an additional 33,831 shares during the last quarter. Citigroup Inc. raised its position in shares of Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company's stock valued at $3,897,000 after acquiring an additional 56,332 shares in the last quarter. Finally, Rosalind Advisors Inc. boosted its holdings in Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company's stock worth $11,578,000 after purchasing an additional 82,000 shares during the period. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, November 28th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO traded down $0.23 during trading hours on Tuesday, hitting $6.11. The stock had a trading volume of 229,503 shares, compared to its average volume of 329,136. The stock's fifty day simple moving average is $6.27 and its 200 day simple moving average is $5.37. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.